Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial.

ABSTRACT:

Background

Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) remains a therapeutic challenge, especially after progression on prior systemic therapies. While immune checkpoint inhibitors combined with antiangiogenic agents have shown synergy in other tumors, data in RAIR-DTC are limited. This study evaluated camrelizumab plus apatinib in first-line and salvage settings.

Methods

This open-label, single-arm, phase II trial (NCT04560127) enrolled patients with locally advanced or metastatic RAIR-DTC. Patients received intravenous camrelizumab (200 mg every 2 weeks) and oral apatinib (250 mg daily) in 4-week cycle until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective respon

SUBMITTER: Zhang X 

PROVIDER: S-EPMC12828957 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature